Cellebrite DI (CLBT) Q4 2025 earnings summary

Executive summary

• Achieved record Q4 and full-year 2025 results, with 21% ARR growth to $481M and strong revenue and profitability, driven by SaaS, AI, and acquisitions including Corellium.

• Strategic progress included Corellium acquisition ($16.1M ARR contribution), launch of Inseyets, SaaS/cloud expansion, and agreement to acquire SCG Canada for drone forensics.

• Outperformed guidance on Q4 revenue and Adjusted EBITDA; Free Cash Flow reached $160.3M with a 34% margin.

• Expanded sales team and talent, and launched AI Innovation Center to drive future growth.

Financial highlights

• Q4 2025 revenue grew 18% year-over-year to $128.8M; full-year revenue up 19% to $475.7M.

• Q4 subscription revenue up 21% to $115.5M; full-year subscription revenue up 21% to $427.0M.

• Q4 Adjusted EBITDA was $38.3M (29.8% margin); full-year Adjusted EBITDA was $127.6M (26.8% margin).

• Free Cash Flow for 2025 was $160.3M (34% margin); ended 2025 with $483.8M in cash and investments.

• Q4 GAAP net income $21.3M; non-GAAP net income $36.7M.

Outlook and guidance

• 2026 ARR guidance: $567M–$573M (18–19% growth); revenue: $565M–$571M (19–20% growth); Adjusted EBITDA: $149M–$155M (26–27% margin).

• Q1 2026 ARR expected at $491M–$493M (20–21% growth); revenue at $126M–$129M (18–20% growth).

• Guidance philosophy now uses tighter ranges, based on renewals pipeline and RPO coverage.

• Management expects accelerated ARR growth, continued SaaS/cloud adoption, and a rebound in U.S. Federal segment.